Sequoia Financial Advisors LLC Cuts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Sequoia Financial Advisors LLC trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 79.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,962 shares of the medical research company's stock after selling 7,569 shares during the period. Sequoia Financial Advisors LLC's holdings in Charles River Laboratories International were worth $362,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares during the period. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International in the third quarter valued at approximately $59,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research reports. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. Barclays dropped their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a report on Tuesday, February 18th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Finally, William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $189.77.

Charles River Laboratories International Stock Up 1.2 %

Shares of Charles River Laboratories International stock traded up $1.94 during trading hours on Friday, hitting $167.29. The company had a trading volume of 1,638,932 shares, compared to its average volume of 723,794. The company's 50-day moving average is $166.11 and its two-hundred day moving average is $183.77. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $274.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market cap of $8.55 billion, a P/E ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same quarter in the prior year, the business posted $2.46 EPS. The company's revenue for the quarter was down 1.1% on a year-over-year basis. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).